ERBB2 and non-small cell lung carcinoma: In the NSCLC Guidelines, predictive molecular biomarkers include: mutations of the KRAS gene (20-30%), epidermal growth factor receptor (EGFR) mutation (10-15% of Caucasian patients and up to 40% of Asian patients), rearrangements of anaplastic lymphoma kinase (ALK) (3-7%), ROS1 (1-2%), RET (1-2%), NTRK (0.5-1%), mutations of the gene BRAF (2-4%), human epidermal growth factor receptor 2 (HER2) mutation (1-4%), amplification (2-5%) and protein overexpression (2-30%) and amplifications or mutations of the MET gene (2-4%) (7–9).